The present disclosure pertains to medical devices, and methods for manufacturing medical devices. More particularly, the present disclosure pertains to leadless cardiac pacing devices including tissue engagement verification features.
Cardiac pacemakers provide electrical stimulation to heart tissue to cause the heart to contract and thus pump blood through the vascular system. Conventional pacemakers typically include an electrical lead that extends from a pulse generator implanted subcutaneously or sub-muscularly to an electrode positioned adjacent the inside or outside wall of the cardiac chamber. As an alternative to conventional pacemakers, self-contained or leadless cardiac pacemakers have been proposed. Leadless cardiac pacemakers are small capsules typically including bipolar pacing/sensing electrodes, a power source (e.g. a battery), and associated electrical circuitry for controlling the pacing/sensing electrodes, and thus provide electrical stimulation to heart tissue and/or sense a physiological condition. The small capsule is typically fixed to an intracardiac implant site in a cardiac chamber with a fixation mechanism engaging the intracardiac tissue.
Accordingly, it is desirable to provide alternative structures to facilitate verification of sufficient engagement of the fixation mechanism into the intracardiac tissue to ensure the leadless cardiac pacemaker is secured to the intracardiac tissue.
The disclosure is directed to several alternative designs, materials and methods of manufacturing medical device structures and assemblies, and uses thereof.
Accordingly one illustrative embodiment is an implantable leadless cardiac pacing device including a housing having a proximal end and a distal end, an electrode positioned proximate the distal end of the housing configured to be positioned adjacent cardiac tissue, and a tissue anchoring member extending from the distal end of the housing configured to secure the housing to cardiac tissue. The device further includes a tissue engagement verification feature configured to provide feedback upon engagement of the tissue anchoring member in cardiac tissue.
Another illustrative embodiment is an implantable leadless cardiac pacing device including a housing having a proximal end and a distal end, an electrode positioned proximate the distal end of the housing configured to be positioned adjacent cardiac tissue, and a tissue anchoring member extending from the distal end of the housing configured to secure the housing to cardiac tissue. The device further includes a radiopaque marker movable relative to the housing and a radiopaque reference point stationary relative to the housing. Displacement of the radiopaque marker relative to the radiopaque reference point provides visual feedback of engagement of the tissue anchoring member in cardiac tissue.
Yet another illustrative embodiment is a method of implanting a leadless cardiac pacing device. The method includes advancing the leadless cardiac pacing device into a chamber of a heart. A tissue anchoring member of the leadless cardiac pacing device is then engaged into cardiac tissue. While engaging the tissue anchor member into the cardiac tissue, displacement of a radiopaque marker of the leadless cardiac pacing device relative to a radiopaque reference point is fluoroscopically observed to confirm engagement of the tissue anchoring member in cardiac tissue.
The above summary of some example embodiments is not intended to describe each disclosed embodiment or every implementation of the aspects of the disclosure.
The disclosure may be more completely understood in consideration of the following detailed description in connection with the accompanying drawings, in which:
While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure.
The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment described may include one or more particular features, structures, and/or characteristics. However, such recitations do not necessarily mean that all embodiments include the particular features, structures, and/or characteristics. Additionally, when particular features, structures, and/or characteristics are described in connection with one embodiment, it should be understood that such features, structures, and/or characteristics may also be used connection with other embodiments whether or not explicitly described unless clearly stated to the contrary.
The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.
Cardiac pacemakers provide electrical stimulation to heart tissue to cause the heart to contract and thus pump blood through the vascular system. Conventional pacemakers typically include an electrical lead that extends from a pulse generator implanted subcutaneously or sub-muscularly to an electrode positioned adjacent the inside or outside wall of the cardiac chamber. As an alternative to conventional pacemakers, self-contained or leadless cardiac pacemakers have been proposed. A leadless cardiac pacemaker may take the form of a relatively small capsule that may be fixed to an intracardiac implant site in a cardiac chamber. It can be readily appreciated that the implantation of a leadless pacing device within a beating heart can be difficult. Accordingly, it may be desirable for a leadless pacing device to include a tissue engagement verification feature to facilitate verification of sufficient engagement of the fixation mechanism into the intracardiac tissue to ensure the leadless cardiac pacemaker is secured to the intracardiac tissue.
Some of the features of the device 10 can be seen in
The docking member 20 may include a head portion 22 and a neck portion 24 extending between the housing 12 and the head portion 22. The head portion 22 may be capable of engaging with a delivery and/or retrieval catheter. For example, the head portion 22 may include a bore or opening 30 formed therein. The ends of the bore 30 may be open or exposed while a central region of the bore 30 may be covered by a section the 34 of the head portion 22, for example. During delivery, the device 10 may be secured to a delivery device by extending a suture through the bore 30. Additionally or alternatively, a portion of the delivery catheter may include projections or lugs that may engage the bore 30. Some additional details of example delivery devices for delivering the device 10 to cardiac tissue are disclosed herein.
The docking member 20 may also be engaged if it is desired to retrieve and/or reposition the device 10. For example, a retrieval catheter may be advanced to a position adjacent to the device 10. A retrieval mechanism such as a snare, tether, arm, or other suitable structure may extend from the retrieval catheter and engage the head portion 22. When suitably engaged, the device 10 may be pulled from the cardiac tissue and, ultimately, removed from the patient or repositioned.
As the name suggests, the anchoring member 18 may be used to anchor the device 10 to the target tissue. A suitable number of anchoring members 18 may be used with the device 10. For example, the device 10 may include one, two, three, four, five, six, seven, eight, or more anchoring members. In at least some embodiments, the anchoring member 18 may take the form of a helix or screw. According to these embodiments, the anchoring member 18 may be threaded or rotated into cardiac tissue. In other instances, the anchoring member 18 may include one or more, or a plurality of tines configured to be anchored into the cardiac tissue. Some additional details of example mechanisms for threading/anchoring the device 10 to cardiac tissue are disclosed herein.
It can be appreciated that in order to securely anchor the device 10 to cardiac tissue with a helical anchoring member 18 or other anchoring member, it may be desirable to provide intraoperative verification of sufficient engagement of the anchoring member 18 into the cardiac tissue to ensure the device 10 is secured to the cardiac tissue. Accordingly, the device 10 may include one or more tissue engagement verification features to provide the medical personnel intraoperative verification of the degree of tissue engagement of the anchoring member 18 during the implantation procedure. Thus, the tissue engagement verification feature may be configured to provide feedback upon engagement of the tissue anchoring member 18 in cardiac tissue. In some embodiments, the tissue engagement verification feature may be movable from a first position relative to the housing 12 to a second position relative to the housing 12. In some instances, the first position may be an equilibrium position, and the second position may be a displaced position through application of an external force, such as through contact with the cardiac tissue. In some embodiments, the tissue engagement verification feature may be arranged with the device 10 such that the tissue engagement verification feature moves toward the proximal end of the housing 12 as the tissue engagement verification feature moves from the first position to the second position. The tissue engagement verification feature may include a radiopaque material to provide intraoperative visual feedback via fluoroscopy during implantation of the device 10 in the heart H. The radiopaque material of the tissue engagement verification feature may be movable relative to the housing 12, such that the movement of the tissue engagement verification feature may be viewed using fluoroscopy during the medical procedure. In some embodiments, the device 10 may include a radiopaque reference point which is stationary relative to the housing 12, such that displacement of the radiopaque material of the tissue engagement verification feature relative to the radiopaque reference point provides visual feedback of engagement of the tissue anchoring member 18 in cardiac tissue.
One exemplary example of tissue engagement verification features which can be included with the device 10 are illustrated in
The form of the tissue engagement verification features 50 may vary. For example, the tissue engagement verification features 50 may take the form of tines 32 projecting from housing 12. In some instances, the tines 32 may be symmetrically or asymmetrically arranged around the perimeter of the housing 12 and extend radially outward therefrom. The tines 32 may extend radially from the housing 12 in a distal direction in a first, equilibrium position, shown in
The tines 32 may be doped with, made of, or otherwise include a radiopaque material. In some instances, the tines 32 may include a radiopaque marker 40, such as at a distal tip of the tines 32, or along another portion of the tines 32. In other instances, the tines 32, or a portion thereof, may be formed of a radiopaque material or be doped with a radiopaque material, and thus serve as the radiopaque marker. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of the device 10 visualizing the radiopaque marker (e.g., the tine 32) using fluoroscopy. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like.
In some instances, the device 10 may also include a radiopaque reference point 60 which is stationary relative to the housing 12, or be included as part of the housing 12. For example the radiopaque reference point 60 may be a radiopaque ring surrounding the housing 12, or another radiopaque structure on the housing 12, or the material forming the housing 12. Accordingly, displacement of the radiopaque material of the tines 32 relative to the radiopaque reference point 60 may provide visual feedback of engagement of the tissue anchoring member 18 in cardiac tissue.
The tines 32 may have any desired cross-sectional shape, such as a generally circular cross-sectional shape. In at least some embodiments, the tines 32 may be substantially straight. In other embodiments, the tines 32 may include one or more curves or bends. A variety of other shapes, forms, and configurations are also contemplated for the tines 32. In addition, some devices may include combinations of differently shaped or oriented tines 32.
The catheter 100 may be advanced through the vasculature to target region 90, with the device 10 positioned in the distal holding section 136 of the delivery catheter 100. For example, the catheter 100 may be advanced through a femoral vein, into the inferior vena cava, into the right atrium, through the tricuspid valve, and into the right ventricle. The target region 90 may be a portion of the right ventricle. For example, the target region 90 may be a portion of the right ventricle near the apex of the heart. In other instances, however, the target region 90 may be in another portion of the heart, such as in another chamber of the heart, for example.
The device 10 may include the anchor member 18 and tissue engagement verification features, such as the tines 32. During advancement of the catheter 100 through the vasculature, the tines 32 may be oriented in the distal direction (e.g., toward the distal end of the device 10 and/or distally from the device 10).
When the device 10 has been positioned proximate the target region 90, the device 10 may be expelled from the distal holding section 136, as shown in
The form of the tissue engagement verification features 150 may vary. For example, the tissue engagement verification features 150 may take the form of a compressible member, such as an open wound coil 132. The open wound coil 132 is shown coaxial with the helical tissue anchoring member 18, with the open wound coil 132 surrounding the tissue anchoring member 18. However, in other embodiments, the open wound coil 132 may be positioned within the helical tissue anchoring member 18, or otherwise disposed. The open wound coil 132 may extend distally from the distal end of the housing 12, for example.
The open wound coil 132 may be constructed such that adjacent windings of the open wound coil 132 are spaced apart a first distance when in a first, uncompressed position, and move closer together with an applied force (e.g., a second, compressed position), such as upon engagement of the open wound coil 132 with cardiac tissue.
The open wound coil 132 may be doped with, made of, or otherwise include a radiopaque material. In some instances, only a discrete portion of the open wound coil 132 may include a radiopaque material, such as at a distal tip of the open wound coil 132, or along another portion of the open wound coil 132, and thus serve as a radiopaque marker. In other instances, the entire open wound coil 132 may be formed of a radiopaque material or be doped with a radiopaque material, and thus serve as a radiopaque marker. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of the device 10 visualizing the radiopaque open wound coil 132 using fluoroscopy. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like.
In some instances, the device 10 may also include a radiopaque reference point which is stationary relative to the housing 12, or be included as part of the housing 12. Accordingly, displacement of the radiopaque open wound coil 132 relative to the radiopaque reference point of the housing 12 (e.g., compression of the open wound coil 132) may provide visual feedback of engagement of the tissue anchoring member 18 in cardiac tissue.
The catheter 100 may be advanced through the vasculature to target region 90, with the device 10 positioned in the distal holding section 136 of the delivery catheter 100. For example, the catheter 100 may be advanced through a femoral vein, into the inferior vena cava, into the right atrium, through the tricuspid valve, and into the right ventricle. The target region 90 may be a portion of the right ventricle. For example, the target region 90 may be a portion of the right ventricle near the apex of the heart. In other instances, however, the target region 90 may be in another portion of the heart, such as in another chamber of the heart, for example.
The device 10 may include the anchor member 18 and tissue engagement verification features, such as the open wound coil 132. During advancement of the catheter 100 through the vasculature, the open wound coil 132, which may extend distally from the distal end of the housing 12, may be in a first, uncompressed position with adjacent windings spaced from one another.
When the device 10 has been positioned proximate the target region 90, the device 10 may be expelled from the distal holding section 136, as shown in
The form of the tissue engagement verification features 250 may vary. For example, the tissue engagement verification features 250 may take the form of a compressible member, such as one or more, or a plurality of deflectable struts 232. The annular ring 240 is shown coaxial with the helical tissue anchoring member 18, with the annular ring 240 surrounding the tissue anchoring member 18. However, in other embodiments, the annular ring 240 may be positioned within the helical tissue anchoring member 18, or otherwise disposed. The struts 232 may extend distally from the distal end of the housing 12, for example. The struts 232 may have a proximal end secured to the housing 12 and a distal end secured to the annular ring 240, for example.
The struts 232 may be configured to deflect, bend, collapse, or otherwise be altered to move the ends of the struts toward one another, when subjected to an external force. The struts 232 may be formed of a flexible material. For example, the struts 232 may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, combinations thereof, and the like, or other suitable material. Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel, a nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol, other nickel alloys. Some examples of suitable polymers may include elastomeric polyamides, polyurethane, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), as well as other suitable materials, or mixtures, combinations, copolymers thereof, and the like.
The tissue engagement verification feature 250 may be constructed such that the distal ends of the struts 232 and/or the annular ring 240 is positioned a first distance from the distal end of the housing 12 when in a first, uncompressed position, and the distal ends of the struts 232 and/or the annular ring 240 is positioned a second distance (e.g., a second, compressed position), less than the first distance (e.g., moved proximally toward the distal end of the housing 12), with an applied force, such as upon engagement of the distal ends of the struts 232 and/or the annular ring 240 with cardiac tissue.
The struts 232 and/or the annular ring 240 may be doped with, made of, or otherwise include a radiopaque material, and thus serve as a radiopaque marker. For example, the annular ring 240 may be formed of a radiopaque material or be doped with a radiopaque material, and thus serve as a radiopaque marker. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of the device 10 visualizing the radiopaque annular ring 240 using fluoroscopy. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like.
In some instances, the device 10 may also include a radiopaque reference point which is stationary relative to the housing 12, or be included as part of the housing 12. For example the radiopaque reference point 60 may be a radiopaque ring surrounding the housing 12, or another radiopaque structure on the housing 12, or the material forming the housing 12. Accordingly, displacement of the radiopaque material of the struts 232 and/or the annular ring 240 relative to the radiopaque reference point 60 may provide visual feedback of engagement of the tissue anchoring member 18 in cardiac tissue.
The catheter 100 may be advanced through the vasculature to target region 90, with the device 10 positioned in the distal holding section 136 of the delivery catheter 100. For example, the catheter 100 may be advanced through a femoral vein, into the inferior vena cava, into the right atrium, through the tricuspid valve, and into the right ventricle. The target region 90 may be a portion of the right ventricle. For example, the target region 90 may be a portion of the right ventricle near the apex of the heart. In other instances, however, the target region 90 may be in another portion of the heart, such as in another chamber of the heart, for example.
The device 10 may include the anchor member 18 and tissue engagement verification features, such as the tissue engagement verification feature 250 including the struts 232 and/or annular ring 240. During advancement of the catheter 100 through the vasculature, the struts 232, which may extend distally from the distal end of the housing 12, may be in a first, uncompressed position positioning the distal ends of the struts 232 and/or annular ring 240 a first distance from the distal end of the housing 12.
When the device 10 has been positioned proximate the target region 90, the device 10 may be expelled from the distal holding section 136, as shown in
The tissue engagement verification feature 350 may be constructed such that the bead 340 is positioned on the helical tissue anchoring member 18 at a first distance from the distal end of the housing 12 when in a first position, and the bead 340 is movable along the tissue anchoring structure 18 such that the bead 340 is positioned a second distance less than the first distance in a second position, as the tissue engagement member 18 is screwed into cardiac tissue.
The bead 340 may be doped with, made of, or otherwise include a radiopaque material, and thus serve as a radiopaque marker. For example, the bead 340 may be formed of a radiopaque material or be doped with a radiopaque material, and thus serve as a radiopaque marker. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of the device 10 visualizing the radiopaque bead 340 using fluoroscopy. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like.
In some instances, the device 10 may also include a radiopaque reference point which is stationary relative to the housing 12, or be included as part of the housing 12. For example the radiopaque reference point 60 may be a radiopaque ring surrounding the housing 12, or another radiopaque structure on the housing 12, or the material forming the housing 12. Accordingly, displacement of the radiopaque bead 340 relative to the radiopaque reference point 60 may provide visual feedback of engagement of the tissue anchoring member 18 in cardiac tissue.
The catheter 100 may be advanced through the vasculature to target region 90, with the device 10 positioned in the distal holding section 136 of the delivery catheter 100. For example, the catheter 100 may be advanced through a femoral vein, into the inferior vena cava, into the right atrium, through the tricuspid valve, and into the right ventricle. The target region 90 may be a portion of the right ventricle. For example, the target region 90 may be a portion of the right ventricle near the apex of the heart. In other instances, however, the target region 90 may be in another portion of the heart, such as in another chamber of the heart, for example.
The device 10 may include the anchor member 18 and tissue engagement verification features, such as the tissue engagement verification feature 350 including the bead 340 slidably coupled to the helical anchoring member 18. During advancement of the catheter 100 through the vasculature, the bead 340, which may be positioned proximate the stop 342, may be in a first position positioning the bead 340 a first distance from the distal end of the housing 12.
When the device 10 has been positioned proximate the target region 90, the device 10 may be expelled from the distal holding section 136, as shown in
It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the disclosure. This may include, to the extent that it is appropriate, the use of any of the features of one example embodiment being used in other embodiments. The invention's scope is, of course, defined in the language in which the appended claims are expressed.
Additional Examples
A first example is an implantable leadless cardiac pacing device including a housing having a proximal end and a distal end, an electrode positioned proximate the distal end of the housing configured to be positioned adjacent cardiac tissue, and a tissue anchoring member extending from the distal end of the housing configured to secure the housing to cardiac tissue. The device further includes a tissue engagement verification feature configured to provide feedback upon engagement of the tissue anchoring member in cardiac tissue.
Additionally or alternatively, in a second example, the tissue engagement verification feature is movable from a first position relative to the housing to a second position relative to the housing.
Additionally or alternatively, in a third example, the first position is an equilibrium position, and the second position is a displaced position through application of an external force.
Additionally or alternatively, in a fourth example, the tissue engagement verification feature moves toward the proximal end of the housing as the tissue engagement verification feature moves from the first position to the second position.
Additionally or alternatively, in a fifth example, the tissue engagement verification feature includes a radiopaque material to provide visual feedback via fluoroscopy.
Additionally or alternatively, in a sixth example, the radiopaque material is movable relative to the housing.
Additionally or alternatively, a seventh example includes radiopaque reference point which is stationary relative to the housing, wherein displacement of the radiopaque material relative to the radiopaque reference point provides visual feedback of engagement of the tissue anchoring member in cardiac tissue.
Additionally or alternatively, in an eighth example, the tissue engagement verification feature includes one or more tines configured to deflect upon engagement with cardiac tissue.
Additionally or alternatively, in a ninth example, the tissue engagement verification feature includes a compressible member configured to compress upon engagement with cardiac tissue.
Additionally or alternatively, in a tenth example, the compressible member includes an open wound coil.
Additionally or alternatively, in an eleventh example, adjacent windings of the open wound coil move closer together upon engagement of the open wound coil with cardiac tissue.
Additionally or alternatively, in a twelfth example, the compressible member includes one or more deflectable struts.
Additionally or alternatively, in a thirteenth example, the one or more deflectable struts extend between the distal end of the housing to a ring comprising a radiopaque material.
Additionally or alternatively, in a fourteenth example, the tissue engagement verification feature includes a radiopaque member configured to move along the tissue anchoring member upon engagement with cardiac tissue.
Additionally or alternatively, in a fifteenth example, the radiopaque member includes a bead slidable along tissue anchoring member.
This application claims the benefit of U.S. Provisional Application Ser. No. 61/985,826, filed Apr. 29, 2014, the disclosure of which is incorporated herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
721869 | Dunning | Mar 1903 | A |
3717151 | Collett | Feb 1973 | A |
3754555 | Schmitt | Aug 1973 | A |
3814104 | Irnich et al. | Jun 1974 | A |
3835864 | Rasor et al. | Sep 1974 | A |
3902501 | Citron et al. | Sep 1975 | A |
3943936 | Rasor | Mar 1976 | A |
3971364 | Fletcher et al. | Jul 1976 | A |
3976082 | Schmitt | Aug 1976 | A |
4103690 | Harris | Aug 1978 | A |
4112952 | Thomas et al. | Sep 1978 | A |
4269198 | Stokes | May 1981 | A |
4280512 | Karr | Jul 1981 | A |
4301815 | Doring | Nov 1981 | A |
4402328 | Doring | Sep 1983 | A |
4409994 | Doring | Oct 1983 | A |
4502492 | Bornzin | Mar 1985 | A |
4662382 | Sluetz et al. | May 1987 | A |
4898577 | Badger et al. | Feb 1990 | A |
4913164 | Greene et al. | Apr 1990 | A |
5003990 | Osypka | Apr 1991 | A |
5057114 | Wittich et al. | Oct 1991 | A |
5129749 | Sato | Jul 1992 | A |
5171233 | Amplatz et al. | Dec 1992 | A |
5193540 | Schulman et al. | Mar 1993 | A |
5257634 | Kroll | Nov 1993 | A |
5282845 | Bush et al. | Feb 1994 | A |
5300107 | Stokes et al. | Apr 1994 | A |
5318528 | Heaven et al. | Jun 1994 | A |
5336253 | Gordon et al. | Aug 1994 | A |
5405367 | Schulman et al. | Apr 1995 | A |
5405374 | Stein | Apr 1995 | A |
5411535 | Fujii et al. | May 1995 | A |
5425756 | Heil et al. | Jun 1995 | A |
5443492 | Stokes et al. | Aug 1995 | A |
5492119 | Abrams | Feb 1996 | A |
5522875 | Gates et al. | Jun 1996 | A |
5522876 | Rusink | Jun 1996 | A |
5545201 | Helland et al. | Aug 1996 | A |
5545206 | Carson | Aug 1996 | A |
5562723 | Rugland et al. | Oct 1996 | A |
5575814 | Giele et al. | Nov 1996 | A |
5578068 | Laske et al. | Nov 1996 | A |
5697936 | Shipko et al. | Dec 1997 | A |
5716390 | Li | Feb 1998 | A |
5716391 | Grandjean | Feb 1998 | A |
5755764 | Schroeppel | May 1998 | A |
5776178 | Pohndorf et al. | Jul 1998 | A |
5807399 | Laske et al. | Sep 1998 | A |
5837006 | Ocel et al. | Nov 1998 | A |
5837007 | Altman et al. | Nov 1998 | A |
5851226 | Skubitz et al. | Dec 1998 | A |
5871531 | Struble | Feb 1999 | A |
5908381 | Aznoian et al. | Jun 1999 | A |
5908447 | Schroeppel et al. | Jun 1999 | A |
6041258 | Cigaina et al. | Mar 2000 | A |
6055457 | Bonner | Apr 2000 | A |
6074401 | Gardnier et al. | Jun 2000 | A |
6078840 | Stokes | Jun 2000 | A |
6093177 | Javier et al. | Jul 2000 | A |
6129749 | Bartig et al. | Oct 2000 | A |
6132456 | Sommer et al. | Oct 2000 | A |
6181973 | Ceron et al. | Jan 2001 | B1 |
6188932 | Lindegren | Feb 2001 | B1 |
6240322 | Peterfeso et al. | May 2001 | B1 |
6251104 | Kesten et al. | Jun 2001 | B1 |
6290719 | Garberoglio | Sep 2001 | B1 |
6321124 | Cigaina | Nov 2001 | B1 |
6322548 | Payne et al. | Nov 2001 | B1 |
RE37463 | Altman | Dec 2001 | E |
6358256 | Reinhardt | Mar 2002 | B1 |
6363938 | Saadat et al. | Apr 2002 | B2 |
6381495 | Jenkins | Apr 2002 | B1 |
6381500 | Fischer, Sr. | Apr 2002 | B1 |
6408214 | Williams et al. | Jun 2002 | B1 |
6458145 | Ravenscroft et al. | Oct 2002 | B1 |
6477423 | Jenkins | Nov 2002 | B1 |
6500182 | Foster | Dec 2002 | B2 |
6510332 | Greenstein | Jan 2003 | B1 |
6510345 | Van Bentem | Jan 2003 | B1 |
6522915 | Ceballos et al. | Feb 2003 | B1 |
6572587 | Lerman et al. | Jun 2003 | B2 |
6582441 | He et al. | Jun 2003 | B1 |
6592581 | Bowe | Jul 2003 | B2 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6626915 | Leveillee | Sep 2003 | B2 |
6638268 | Niazi | Oct 2003 | B2 |
6684109 | Osypka | Jan 2004 | B1 |
6711443 | Osypka | Mar 2004 | B2 |
6743240 | Smith et al. | Jun 2004 | B2 |
6755812 | Peterson et al. | Jun 2004 | B2 |
6909920 | Lokhoff et al. | Jun 2005 | B2 |
6944507 | Fröberg et al. | Sep 2005 | B2 |
6953454 | Peterson et al. | Oct 2005 | B2 |
7027876 | Casavant et al. | Apr 2006 | B2 |
7082335 | Klein et al. | Jul 2006 | B2 |
7085606 | Flach et al. | Aug 2006 | B2 |
7092765 | Geske et al. | Aug 2006 | B2 |
7092766 | Salys et al. | Aug 2006 | B1 |
7120504 | Osypka | Oct 2006 | B2 |
7149587 | Wardle et al. | Dec 2006 | B2 |
7158838 | Seifert et al. | Jan 2007 | B2 |
7162310 | Doan | Jan 2007 | B2 |
7181288 | Rezai et al. | Feb 2007 | B1 |
7187982 | Seifert et al. | Mar 2007 | B2 |
7200437 | Nabutovsky et al. | Apr 2007 | B1 |
7212869 | Wahlstrom et al. | May 2007 | B2 |
7229415 | Schwartz | Jun 2007 | B2 |
7251532 | Hess et al. | Jul 2007 | B2 |
7289853 | Campbell et al. | Oct 2007 | B1 |
7313445 | McVenes et al. | Dec 2007 | B2 |
7326231 | Phillips et al. | Feb 2008 | B2 |
7328071 | Stehr et al. | Feb 2008 | B1 |
7383091 | Chitre et al. | Jun 2008 | B1 |
7450999 | Karicherla et al. | Nov 2008 | B1 |
7462184 | Worley et al. | Dec 2008 | B2 |
7463933 | Wahlstrom et al. | Dec 2008 | B2 |
7499758 | Cates et al. | Mar 2009 | B2 |
7509169 | Eigler et al. | Mar 2009 | B2 |
7515971 | Doan | Apr 2009 | B1 |
7532939 | Sommer et al. | May 2009 | B2 |
7558631 | Cowan et al. | Jul 2009 | B2 |
7634319 | Schneider et al. | Dec 2009 | B2 |
7647109 | Hastings et al. | Jan 2010 | B2 |
7657325 | Williams | Feb 2010 | B2 |
7678128 | Boyle et al. | Mar 2010 | B2 |
7717899 | Bowe et al. | May 2010 | B2 |
7731655 | Smith et al. | Jun 2010 | B2 |
7734343 | Ransbury et al. | Jun 2010 | B2 |
7740640 | Ginn | Jun 2010 | B2 |
7785264 | Hettrick et al. | Aug 2010 | B2 |
7799037 | He et al. | Sep 2010 | B1 |
7801624 | Flannery et al. | Sep 2010 | B1 |
7835801 | Sundararajan et al. | Nov 2010 | B1 |
7840281 | Kveen et al. | Nov 2010 | B2 |
7840283 | Bush et al. | Nov 2010 | B1 |
7860580 | Falk et al. | Dec 2010 | B2 |
7875049 | Eversull et al. | Jan 2011 | B2 |
7890186 | Wardle et al. | Feb 2011 | B2 |
7904179 | Ruffen et al. | Mar 2011 | B2 |
7920928 | Yang et al. | Apr 2011 | B1 |
7993351 | Worley et al. | Aug 2011 | B2 |
8010209 | Jacobson | Aug 2011 | B2 |
8036757 | Worley | Oct 2011 | B2 |
8057486 | Hansen | Nov 2011 | B2 |
8082035 | Glukhovsky | Dec 2011 | B2 |
8103361 | Moser | Jan 2012 | B2 |
8108054 | Helland | Jan 2012 | B2 |
8142347 | Griego et al. | Mar 2012 | B2 |
8160722 | Rutten et al. | Apr 2012 | B2 |
8185213 | Kveen et al. | May 2012 | B2 |
8219213 | Sommer et al. | Jul 2012 | B2 |
8233994 | Sommer et al. | Jul 2012 | B2 |
8252019 | Fleming, III | Aug 2012 | B2 |
8295939 | Jacobson | Oct 2012 | B2 |
8313445 | Mishima et al. | Nov 2012 | B2 |
8352025 | Jacobson | Jan 2013 | B2 |
8352028 | Wenger | Jan 2013 | B2 |
8364277 | Glukhovsky | Jan 2013 | B2 |
8364280 | Marnfeldt et al. | Jan 2013 | B2 |
8406900 | Barlov et al. | Mar 2013 | B2 |
8406901 | Starkebaum et al. | Mar 2013 | B2 |
8428750 | Kolberg | Apr 2013 | B2 |
8452420 | Flach et al. | May 2013 | B2 |
8478431 | Griswold et al. | Jul 2013 | B2 |
8489189 | Tronnes | Jul 2013 | B2 |
8494650 | Glukhovsky et al. | Jul 2013 | B2 |
8504156 | Bonner et al. | Aug 2013 | B2 |
8518060 | Jelich et al. | Aug 2013 | B2 |
8527068 | Ostroff | Sep 2013 | B2 |
8532790 | Griswold | Sep 2013 | B2 |
8548605 | Ollivier | Oct 2013 | B2 |
8565897 | Regnier et al. | Oct 2013 | B2 |
8615310 | Khairkhahan et al. | Dec 2013 | B2 |
8634912 | Bornzin et al. | Jan 2014 | B2 |
8670842 | Bornzin et al. | Mar 2014 | B1 |
8721587 | Berthiaume et al. | May 2014 | B2 |
8727996 | Allan et al. | May 2014 | B2 |
8758365 | Bonner et al. | Jun 2014 | B2 |
20020077556 | Schwartz | Jun 2002 | A1 |
20030004537 | Boyle et al. | Jan 2003 | A1 |
20040116992 | Wardle et al. | Jun 2004 | A1 |
20040176797 | Opolski | Sep 2004 | A1 |
20050090890 | Wu et al. | Apr 2005 | A1 |
20050267555 | Marnfeldt et al. | Dec 2005 | A1 |
20060247753 | Wenger et al. | Nov 2006 | A1 |
20070135883 | Drasler et al. | Jun 2007 | A1 |
20070150037 | Hastings et al. | Jun 2007 | A1 |
20070150038 | Hastings et al. | Jun 2007 | A1 |
20070233218 | Kolberg | Oct 2007 | A1 |
20070239248 | Hastings et al. | Oct 2007 | A1 |
20070255376 | Michels et al. | Nov 2007 | A1 |
20070276444 | Gelbart | Nov 2007 | A1 |
20070293904 | Gelbart | Dec 2007 | A1 |
20080021532 | Kveen et al. | Jan 2008 | A1 |
20090082828 | Ostroff | Mar 2009 | A1 |
20090281605 | Marnfeldt et al. | Nov 2009 | A1 |
20100198288 | Ostroff | Aug 2010 | A1 |
20110034939 | Kveen et al. | Feb 2011 | A1 |
20110112548 | Fifer et al. | May 2011 | A1 |
20110125163 | Rutten et al. | May 2011 | A1 |
20110190785 | Gerber et al. | Aug 2011 | A1 |
20110190786 | Gerber et al. | Aug 2011 | A1 |
20110208260 | Jacobson | Aug 2011 | A1 |
20110237967 | Moore et al. | Sep 2011 | A1 |
20110270339 | Murray, III et al. | Nov 2011 | A1 |
20110270340 | Pellegrini et al. | Nov 2011 | A1 |
20110282423 | Jacobson | Nov 2011 | A1 |
20110307043 | Ollivier | Dec 2011 | A1 |
20120078322 | Dal Molin et al. | Mar 2012 | A1 |
20120078336 | Helland | Mar 2012 | A1 |
20120095539 | Khairkhahan et al. | Apr 2012 | A1 |
20120109002 | Mothilal et al. | May 2012 | A1 |
20120109079 | Asleson et al. | May 2012 | A1 |
20120109148 | Bonner et al. | May 2012 | A1 |
20120109149 | Bonner et al. | May 2012 | A1 |
20120116489 | Khairkhahan et al. | May 2012 | A1 |
20120158111 | Khairkhahan et al. | Jun 2012 | A1 |
20120165827 | Khairkhahan et al. | Jun 2012 | A1 |
20120172690 | Anderson et al. | Jul 2012 | A1 |
20120172891 | Lee | Jul 2012 | A1 |
20120172892 | Grubac et al. | Jul 2012 | A1 |
20120197373 | Khairkhahan et al. | Aug 2012 | A1 |
20120232565 | Kveen et al. | Sep 2012 | A1 |
20120271134 | Allan et al. | Oct 2012 | A1 |
20120330392 | Regnier et al. | Dec 2012 | A1 |
20130006261 | Lampropoulos et al. | Jan 2013 | A1 |
20130006262 | Lampropoulos et al. | Jan 2013 | A1 |
20130012925 | Berthiaume et al. | Jan 2013 | A1 |
20130035636 | Beasley et al. | Feb 2013 | A1 |
20130035748 | Bonner et al. | Feb 2013 | A1 |
20130053921 | Bonner et al. | Feb 2013 | A1 |
20130079798 | Tran et al. | Mar 2013 | A1 |
20130079861 | Reinert et al. | Mar 2013 | A1 |
20130103047 | Steingisser et al. | Apr 2013 | A1 |
20130103049 | Bonde | Apr 2013 | A1 |
20130116740 | Bornzin | May 2013 | A1 |
20130116741 | Bornzin et al. | May 2013 | A1 |
20130123875 | Varady et al. | May 2013 | A1 |
20130131591 | Berthiaume et al. | May 2013 | A1 |
20130131693 | Berthiaume et al. | May 2013 | A1 |
20130253342 | Griswold et al. | Sep 2013 | A1 |
20130253343 | Waldhauser et al. | Sep 2013 | A1 |
20130253344 | Griswold et al. | Sep 2013 | A1 |
20130253345 | Griswold et al. | Sep 2013 | A1 |
20130253346 | Griswold et al. | Sep 2013 | A1 |
20130253347 | Griswold et al. | Sep 2013 | A1 |
20130296957 | Tronnes | Nov 2013 | A1 |
20140058494 | Ostroff et al. | Feb 2014 | A1 |
20140074114 | Khairkhahan et al. | Mar 2014 | A1 |
20140148815 | Wenzel et al. | May 2014 | A1 |
20140180306 | Grubac et al. | Jun 2014 | A1 |
20150025612 | Haasl et al. | Jan 2015 | A1 |
20150051609 | Schmidt et al. | Feb 2015 | A1 |
20150051610 | Schmidt et al. | Feb 2015 | A1 |
20150051611 | Schmidt et al. | Feb 2015 | A1 |
20150051612 | Schmidt et al. | Feb 2015 | A1 |
20150051613 | Schmidt et al. | Feb 2015 | A1 |
20150051614 | Schmidt et al. | Feb 2015 | A1 |
20150051615 | Schmidt et al. | Feb 2015 | A1 |
20150051616 | Haasl et al. | Feb 2015 | A1 |
20150051682 | Schmidt et al. | Feb 2015 | A1 |
Number | Date | Country |
---|---|---|
1003904 | Jan 1977 | CA |
2053919 | May 1972 | DE |
779080 | May 2003 | EP |
05245215 | Sep 1993 | JP |
03032807 | Apr 2003 | WO |
2009039400 | Mar 2009 | WO |
2012092067 | Jul 2012 | WO |
2012092074 | Jul 2012 | WO |
Entry |
---|
Spickler, et al. “Totally Self-Contained Intracardiac Pacemaker” J. Electrocardiology, vol. 3, Nos. 3 & 4, pp. 325-331 (1970). |
Number | Date | Country | |
---|---|---|---|
20150306378 A1 | Oct 2015 | US |
Number | Date | Country | |
---|---|---|---|
61985826 | Apr 2014 | US |